<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149733">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989988</url>
  </required_header>
  <id_info>
    <org_study_id>MSIRB2013003</org_study_id>
    <secondary_id>MSIRB2013003</secondary_id>
    <nct_id>NCT01989988</nct_id>
  </id_info>
  <brief_title>DMBSS-A Randomized Trial of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM</brief_title>
  <acronym>DMBSS</acronym>
  <official_title>A Randomized Trial Study of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Min-Sheng General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Min-Sheng General Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to conduct a randomized clinical trial to compare the efficacy
      of diabetes treatment between different gastric bypass procedures involving type 2 diabetics
      patients with BMI from 27.5 to 35 kg/m2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators would like to conduct a randomized clinical trial to compare the efficacy
      of diabetes treatment between different gastric bypass procedures involving type 2 diabetics
      patients with BMI from 27.5 to 35 kg/m2. This program will determine the relative
      effectiveness among LMGB 、RYGB and SADJB .The primary end point including HbA1C&lt;6.0%,
      LDL-C&lt;100mg/dl and SBP&lt;130mmHg at one year after surgery. Through this study, the
      investigators may understand which gastric bypass is the best for type 2 diabetic's
      treatment. The investigators also hope some new treatment modulation may be developed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Remission of diabetes</measure>
    <time_frame>two years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>remission of Diabetes Mellitus Type 2 after different types of Gastric bypass surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight loss and improvement in quality of life</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>weight loss and improvements in quality of life after different types of gastric bypass surgery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus Type 2 in Obese</condition>
  <arm_group>
    <arm_group_label>LRYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects Randomized will undergo LRYGB surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SADJB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects will undergo SADJB surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 subjects will undergo LMGB surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LMGB</intervention_name>
    <arm_group_label>LMGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LRYGB</intervention_name>
    <arm_group_label>LRYGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SADJB</intervention_name>
    <arm_group_label>SADJB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20 to 67 years

          -  Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a
             doctor for at least the six months prior to enrollment, HbA1c ≥ 7.5 %

          -  Body Mass Index (BMI) ≥ 27.5 kg/m 2  and ≤ 34.9 kg/m 2

          -  Willingness to accept random assignment to either treatment group.

          -  Willingness to comply with the follow-up protocol

          -  Written informed consent.

        Exclusion Criteria:

          -  Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery
             angioplasty or bypass, stroke) in the past six months.

          -  Current evidence of congestive heart failure, angina pectoris, or symptomatic
             peripheral vascular disease.

          -  Cardiac stress test indicating that surgery would not be safe.

          -  Pulmonary embolus or thrombophlebitis in the past six months

          -  Cancer of any kind (except basal cell skin cancer or cancer in situ) unless
             documented to be disease-free for five years

          -  Serum creatinine ≥ 1.5 mg/dl

          -  History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or
             colon resection

          -  Previous organ transplantation.

          -  History of alcohol or drug dependency

          -  Current participation in a conflicting research protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Jei Lee, M.D., PH.D</last_name>
    <role>Study Chair</role>
    <affiliation>Min-Sheng General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Min-Sheng General Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <zip>330</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Min-Sheng General Hospital</investigator_affiliation>
    <investigator_full_name>WEI-CHENG YAO</investigator_full_name>
    <investigator_title>Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus (T2DM)</keyword>
  <keyword>Obesity</keyword>
  <keyword>Laparoscopic gastric bypass</keyword>
  <keyword>Duodenum exclusion</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
